Background
Phase III 2×2 factorial RCT. 1,222 patients aged 61–80 years with aggressive B-cell NHL (predominantly DLBCL). Randomized to 6 or 8 cycles of CHOP-14 with or without rituximab; R-CHOP arms received 2 additional rituximab infusions after the last chemotherapy cycle. Conducted by the German High-Grade Lymphoma Study Group (DSHNHL); pivotal trial establishing R-CHOP as standard in elderly DLBCL.
Interventions and follow up
Arm A: Rituximab 375 mg/m² + CHOP-14 × 6 cycles, then 2 additional rituximab doses (total 8 infusions)
Arm B: CHOP-14 × 6 cycles (no-rituximab comparator); 2×2 factorial also included CHOP-14×8 and R-CHOP-14×8+2R arms (4 arms total); G-CSF prophylaxis mandatory for all arms
Primary endpoint: Event-free survival (EFS)
Median follow up: 35 months
Arm B: CHOP-14 × 6 cycles (no-rituximab comparator); 2×2 factorial also included CHOP-14×8 and R-CHOP-14×8+2R arms (4 arms total); G-CSF prophylaxis mandatory for all arms
Primary endpoint: Event-free survival (EFS)
Median follow up: 35 months
Results
3-year EFS (R-CHOP-14×6+2R vs CHOP-14×6): 47.2% vs 32.5%
3-year EFS (rituximab pooled vs CHOP pooled): 45.5% vs 31.1% — HR 0.63, P<.001
6 vs 8 cycles (R-CHOP groups): HR 0.94 — not significant
3-year OS (rituximab vs no-rituximab): 78.1% vs 71.8% — HR 0.73, P=.005
3-year EFS (rituximab pooled vs CHOP pooled): 45.5% vs 31.1% — HR 0.63, P<.001
6 vs 8 cycles (R-CHOP groups): HR 0.94 — not significant
3-year OS (rituximab vs no-rituximab): 78.1% vs 71.8% — HR 0.73, P=.005
Adverse events
Hematologic (grade ≥3): Neutropenia 78% (R-CHOP arms) vs 75% (CHOP arms); G-CSF mandatory in all arms
Cardiac: Grade ≥3 events ~4% each arm
Mortality: Treatment-related mortality 1–2%; no significant excess in severe non-hematologic toxicity with rituximab
Cardiac: Grade ≥3 events ~4% each arm
Mortality: Treatment-related mortality 1–2%; no significant excess in severe non-hematologic toxicity with rituximab
Conclusions
Addition of rituximab to CHOP-14 significantly improved EFS and OS in elderly DLBCL, establishing R-CHOP-14×6 as a standard of care. Extending treatment to 8 cycles conferred no additional benefit over 6 cycles and added toxicity burden.
Key Limitations
Population restricted to ages 61–80; very elderly (≥81y) or frail patients excluded, limiting generalizability. Mandatory G-CSF complicates adoption in lower-resource settings. Some non-DLBCL aggressive subtypes included without separate analysis. Enrollment era predated molecular subtyping (GCB vs ABC, double-hit) and modern risk stratification.
Clinical Context
RICOVER-60, with GELA LNH-98.5, definitively established R-CHOP as the global standard for DLBCL (endorsed by ESMO). The 6-cycle regimen is now guideline-standard; 8 cycles are not recommended. R-CHOP-21 and R-CHOP-14 have similar efficacy by indirect comparison; R-CHOP-21×6 became the dominant worldwide standard.